Mechanisms of pain in angina pectoris—A critical review of the adenosine hypothesis Christer Sylvén Reviews Pages: 745 - 759
Modifying serum lipids to prevent coronary heart disease: Do we have a consensus? Steven A. Grover The Cholesterol Controversy Pages: 761 - 765
Lowering blood lipids to treat atherosclerosis: Vascular tone, plaques, events, and mortality Paolo RubbaPaolo PauciulloMario Mancini The Cholesterol Controversy Pages: 767 - 774
Treating mild hypercholesterolemia in the absence of overt cardiovascular disease: If, when, and why? M. ManciniP. Rubba The Cholesterol Controversy Pages: 775 - 777
Cholesterol confusion in primary prevention of coronary artery disease L. H. Opie The Cholesterol Controversy Pages: 779 - 784
Lowering cholesterol for prevention of coronary heart disease—Problems and perspectives Michael F. Oliver The Cholesterol Controversy Pages: 785 - 788
Does low cholesterol cause death? Jacques E. RossouwAntonio M. Gotto Jr. The Cholesterol Controversy Pages: 789 - 793
Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice Tsugiyasu KandaMasahiro InoueKazuhiko Murata Experimental Pharmacology Pages: 795 - 800
Intracoronary trimetazidine does not improve recovery of regional function in a porcine model of repeated ischemia M. M. G. KoningR. KramsP. D. Verdouw Experimental Pharmacology Pages: 801 - 807
Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction Marco TubaroGiorgio MattioliFilippo Milazzotto Hernostasis And Thrombolysis Pages: 809 - 816
Influences of lipid-modifying agents on hemostasis Cesare R. SirtoriSusanna Colli Hernostasis And Thrombolysis Pages: 817 - 823
Thrombolytic agents and anticoagulants Richard C. Becker Drugs In The Early Stages Of Development Pages: 825 - 828
Assurance against drug-induced death in patients with heart failure Thomas S. Rector Editorial Comment Pages: 829 - 830
